Targeting type 2 inflammation in bullous pemphigoid: dupilumab as a game changer opens new avenues

被引：0
|
作者：
Borradori, Luca [1 ]
Hertl, Michael [2 ]
机构：
[1] Univ Bern, Univ Hosp Bern, Dept Dermatol, Bern, Switzerland
[2] Philipps Univ, Dept Dermatol & Allergol, Marburg, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2025年 / 192卷 / 03期
关键词：
D O I：
10.1093/bjd/ljae465
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：377 / 378
页数：2
相关论文
共 50 条
  • [31] Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes
    Douros, Antonios
    Rouette, Julie
    Yin, Hui
    Yu, Oriana Hoi Yun
    Filion, Kristian B.
    Azoulay, Laurent
    DIABETES CARE, 2019, 42 (08) : 1496 - 1503
  • [32] The Risk Factors of Bullous Pemphigoid and Associated Risk between Bullous Pemphigoid and Dipeptidyl Peptidase-IV Inhibitors in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study
    Guo, Jia-Yin
    Chen, Hsin Hung
    Yang, Yu-Cih
    Chen, Ching-Chu
    DIABETES, 2019, 68
  • [33] Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?
    Seidu, Samuel
    Mellbin, Linda
    Kaiser, Marcel
    Khunti, Kamlesh
    PRIMARY CARE DIABETES, 2021, 15 (01) : 59 - 68
  • [34] BP230-type bullous pemphigoid (a new disease entity?): A case series and a review of literature
    Zhao, C. Y.
    Chiang, Y. Z.
    Melbourne, W.
    Ishii, N.
    Hashimoto, T.
    Murrell, D. F.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 29 - 30
  • [35] Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab
    Benzecry, V
    Pravettoni, V
    Segatto, G.
    Marzano, A., V
    Ferrucci, S.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2021, 31 (03) : 261 - +
  • [36] Dupilumab improve acquired reactive perforating collagenosis characterized by type 2 inflammation
    Liu, Ben
    Wu, Yibei
    Wu, Xiaoyan
    Zhong, Xinyu
    Xue, Ruzeng
    Zhang, Zhenying
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [37] Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils
    Bhatt, S.
    Watz, H.
    Rabe, K.
    Hanania, N.
    Vogelmeier, C.
    Cole, J.
    Bafadhel, M.
    Christenson, S.
    Papi, A.
    Singh, D.
    Laws, E.
    Lu, X.
    Bauer, D.
    Mortensen, E.
    Maloney, J.
    Bansal, A.
    Robinson, L.
    Abdulai, R.
    PNEUMOLOGIE, 2024, 78 : S64 - S64
  • [38] New avenues for the pharmacological management of type 2 diabetes: An update
    Cuny, Thomas
    Guerci, Bruno
    Cariou, Bertrand
    ANNALES D ENDOCRINOLOGIE, 2012, 73 (05) : 459 - 468
  • [39] Targeting T2 Inflammation by Dupilumab Impacts on the Microbiomic "Menage a Trois" of Atopic Dermatitis
    Bieber, Thomas
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (01) : 15 - 17
  • [40] Dipeptidyl peptidase-4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes
    Rouette, Julie
    Douros, Antonios
    Yin, Hui
    Yu, Oriana Hoi Yun
    Filion, Kristian B.
    Azoulay, Laurent
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB47 - AB47
12345